Vor Biopharma upgraded to Buy at Stifel on telitacicept prospects

Group 1 - The shares of Vor Biopharma have increased by 13% today [3] - Vor Biopharma has been upgraded to a Buy rating from Hold by Stifel [3] - The upgrade is based on growing confidence in the long-term potential of the company's lead asset, telitacicept [3]